Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136352 | 0.73 | TP53 (0.32) | CYP1A2ABHD16A | |
| SCHEMBL11859129 | 0.71 | CYP1A2 (0.34) | CYP1A2ABHD16A | |
| SCHEMBL7887401 | 0.69 | PTGS1 (0.42) | CYP1A2 | |
| SCHEMBL8607884 | 0.68 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL11855850 | 0.67 | ELANE (0.34) | CYP1A2 | |
| SCHEMBL2278997 | 0.67 | PTPN1 (0.35) | CYP1A2 | |
| SCHEMBL8029695 | 0.67 | MMP1 (0.38) | — | |
| SCHEMBL4129548 | 0.65 | PTPN1 (0.32) | CYP1A2 | |
| SCHEMBL818514 | 0.63 | — | — | |
| SCHEMBL8032985 | 0.63 | ALDH1A1 (0.33) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| WO-2010124237-A1 | METHODS OF TREATING INFECTIONS OF THE NAIL | NOVABAY PHARMACEUTICALS INC. (US) | 2010-10-28 | — | — | WO | claimed |
| US-20090239907-A1 | METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES | HALOSOURCE, INC. (US) | 2009-09-24 | — | — | US | claimed |
| EP-1996187-A2 | METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES | Halosource, Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2008115225-A2 | METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES | HALOSOURCE, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| EP-0513239-B1 | N,N'-DIHALOIMIDAZOLIDIN-4-ONES | UNIV AUBURN (US) | 1998-04-08 | — | — | EP | claimed |
| US-8563587-B2 | Methods and compositions for treating fish diseases | HALOSOURCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2531026-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097324-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | NOVABAY PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2010124237-A1 | METHODS OF TREATING INFECTIONS OF THE NAIL | NOVABAY PHARMACEUTICALS INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20090239907-A1 | METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES | HALOSOURCE, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2008115225-A2 | METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES | HALOSOURCE, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-0513239-B1 | N,N'-DIHALOIMIDAZOLIDIN-4-ONES | UNIV AUBURN (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0513239-A4 | N,N'-DIHALOIMIDAZOLIDIN-4-ONES | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0513239-A1 | N,N'-DIHALOIMIDAZOLIDIN-4-ONES | AUBURN UNIVERSITY (US) | 1992-11-19 | — | — | EP | disclosed |
| US-5126057-A | Stabilizers against solar radiation | AUBURN RESEARCH FOUNDATION (US) | 1992-06-30 | — | — | US | disclosed |
| US-5057612-A | Stable, noncorrosive bicoide, disinfectant | AUBURN RESEARCH FOUNDATION (US) | 1991-10-15 | — | — | US | disclosed |
| WO-1991010623-A1 | N,N'-DIHALOIMIDAZOLIDIN-4-ONES | AUBURN UNIVERSITY (US) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | CYP1A2 689/4885ABHD16A 3679/4885 |
| US-20090239907-A1 | METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES | AQP3, AQP1, NISCH | CYP1A2 1522/4885ABHD16A 746/4885 |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | FUT6, FUT5, OGT | CYP1A2 2672/4885ABHD16A 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.